Headquartered in Zhongshan, China, with a goal of becoming a global leader in innovative therapeutic antibodies, the company operates a diversified antibody drug pipeline covering over 20 drug development programs. Recent clinical data shows Akeso's immunotherapy drug has outperformed leading Western peers in studies, earning recognition as the 'DeepSeek moment' for China's drug industry.
Cyborg Score Rationale
With a market cap of ~$93.68B and 3,529 employees, Akeso represents significant scale in Chinese biotech. The company has demonstrated strong clinical performance with drugs outperforming Western competitors, supported by recent strong annual reports showing 25% drug sales growth. Early-stage profitability challenges and clinical-stage focus present execution risks.
Top Insights
Strategic partnerships with Merck and other pharma companies provide commercialization and development support for pipeline advancement.
Revenue primarily earned in Mainland China with growing presence in USA and other regions, diversifying commercial risk.
Negative P/E ratio of -99.9 and 0% dividend yield indicate pre-profitability stage typical for clinical-stage biotech companies.
Marketed products include cadonilimab, ivonescimab, and penpulimab for tumor treatment, with additional candidates in autoimmune and metabolic disease areas.
Named Competitors
Keytruda — PD-1 monoclonal antibody for oncology
Tecentriq — PD-L1 checkpoint inhibitor for solid tumors
BNT327 — Immuno-oncology asset in clinical development
Innovent Biologics Pipeline — Chinese biotech competitor with multiple oncology candidates
Recent Developments
(February 2026) Stock trading at HK$127.60 with analyst consensus target of HK$169.65 representing 33% upside
(January 2026) Market cap reached ~$93.68B with recent strong annual report driving 18% stock rally
(2025) Drug sales increased 25% year-over-year with expanded clinical pipeline reaching 17 drugs in clinical stage
Open the full interactive Akeso, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.